Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers

Annals of Pharmacotherapy

Volumn 32, Issue 3, 1998, Pages 304-308

  Tenero, David M ^a   Martin, David E ^b   Ilson, Bernard E ^c   Boyle, Duane A ^a   Boike, Steven C ^c   Carr, Alison M ^a   Lundberg, David E ^a   Jorkasky, Diane K ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Eprosartan; Pharmacokinetics; Ranitidine

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; EPROSARTAN; RANITIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG SAFETY; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PH; TABLET;

ACRYLATES; ADMINISTRATION, ORAL; ADULT; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; HISTAMINE H2 ANTAGONISTS; HUMANS; IMIDAZOLES; MALE; RANITIDINE; THIOPHENES;

EID: 0031934526     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17188     Document Type: Article

References (14)

1. Ferrario CM. Importance of the renin-angiotensin-aldosterone system (RAS) in the physiology and pathology of hypertension: an overview. Drugs 1990;39(suppl 2):1-8.
2. Weinstock J, Keenan RM, Samanen J, Hempel J, Finkelstein JA, Franz RG, et al. 1-(Carboxy-benzyl)imidazole-5-acrylic acids: potent and selective angiotensin n receptor antagonists. J Med Chem 1991;34:1514-7.
3. Csajka C, Buclin T, Brunner HR, Biollaz J. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet 1997;32:1-29.
4. Edwards RM, Aiyar N, Ohlstein EH, Weidley EF, Griffin E, Ezekiel M, et al. Pharmacological characterization of the non-peptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992;260: 175-81.
5. Ilson B, Boike S, Audet P, Freed M, Everitt D, Brown L, et al. Renal hemodynamic effects of SK&F 108566, a nonpeptide selective angiotensin (AII) antagonist (abstract). Clin Pharmacol Ther 1994;55:206.
6. Cox PJ, Bush BD, Gorycki PD, Kuo GY, Kenworthy D, Law DW, et al. The metabolic fate of eprosartan in healthy volunteers. Exp Toxic Pathol 1996;48(suppl II):75-82.
7. Tenero D, Martin D, Ilson B, Jushchyshyn J, Boike S, Lundberg D, et al. Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food. Biopharmaceut Drug Dispos (in press).
8. Lipsy RJ, Fennerty B, Fagan TC. Clinical review of histamine 2 receptor antagonists. Arch Intern Med 1990;150:745-51.
9. Package insert. Zantac (ranitidine HCl). Research Triangle Park, NC: Glaxo Wellcome.
10. Lundberg DE, Person CR, Knox S, Cyronak M. Determination of SK&F 108566 in human plasma by solid-phase extraction cleanup and reversed-phase high-performance liquid chromatography. J Chromatogr (in press).
11. Data on file. King of Prussia, PA: SmithKline Beecham Pharmaceuticals.
12. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Bamett JL, et al. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res 1990;7:756-61.
13. Kosoglou T, Vlasses PH. Drug interactions involving renal transport mechanisms: an overview. DICP Ann Pharmacother 1989;23:116-22.
14. Grant S, Langtry H, Brogden R. Ranitidine: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 1989;37:801-70.